Original Article : Safety and Efficacy Assessment of Mesenchymal Stem Cells from Canine Adipose Tissue or Umbilical Cord Blood in a Canine Osteochondral Defect Model
분야
의약학 > 의공학
저자
( Hyung Jun Choi ) , ( Eu Na Kwon ) , ( Jae Il Lee ) , ( Jeong Hwan Che ) , ( Jong Rhan Kim ) , ( Yeong Geon Lee ) , ( Yun Hyeok Jeong ) , ( Yong Soon Lee ) , ( Kyung Sun Kang ) , ( Byoung Hyun Min ) , ( Byeong Cheol Kang )
발행기관
한국조직공학·재생의학회
간행물정보
조직공학과 재생의학 2009년, 제6권 제14호, 1381~1390페이지(총10페이지)
파일형식
2a800455.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    4,500원
    적립금
    135원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Mesenchymal stem cell (MSC) therapy has emerged as a potentially powerful tool for osteochondral repair, but the safety of stem cells in vivo is still not clear. In this study, we assessed the safety and efficacy of canine adipose tissue-derived MSCs (cATMSCs) or umbilical cord blood-derived MSCs (cUCBMSCs) in osteochondral repair. The test cells were implanted at the site of an osteochondral defect surgically created on the trochlear groove of beagle dogs. To address safety concerns in this model, we conducted a GLP-compliant study. We observed no significant treatment-related changes in body weights, clinical signs, food consumption, hematological or biochemical values, organ weights, or histopathological findings. The stem cell implants induced no detectable tumor formation or local or systemic rejection reaction. In the assessment of effectiveness, 13-week samples from both the cATMSC- and cUCBMSC-implanted groups showed fibrous tissue formation in the extracellular matrix scaffold of the defect similar to that of controls. However, repaired tissues in stem cell-seeded groups showed partial differentiation toward an osteochondral phenotype. These findings support the safety of cATMSC or cUCBMSC transplantation, and show that the cells may potentially differentiate into osteochondral tissues in our canine model. Our study provides a framework in which to establish preclinical safety standards for the development of cellular therapeutics.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.